IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0
IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

Departure of Chief Financial Officer

On November 29, 2018 Atabak Mokari announced that he is resigning as Chief Financial Officer and Vice President of Corporate Development of Iridex Corporation (the “Company”), effective as of December 18, 2018. Mr. Mokari is not resigning due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01.

Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release dated December 4, 2018.


IRIDEX CORP Exhibit
EX-99.1 2 irix-ex991_6.htm EX-99.1 irix-ex991_6.htm Exhibit 99.1    IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance Mountain View,…
To view the full exhibit click here

About IRIDEX CORPORATION (NASDAQ:IRIX)

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.